Simris picks amanitin route for ADC push, with clinic targeted for 2028

Swedish biologics company Simris Group (Nasdaq First North Growth Market: SIMRIS) has settled on amanitin as the basis of its antibody-drug conjugate work, and says it intends to take two proprietary programs into clinical development by late 2027 or early 2028.

In March the company set out two options: continue preclinical development of its microcystin payload platform, or follow a more capital-intensive path by bringing in an experienced ADC team and a payload class already tested in patients. The board has chosen the second, while continuing microcystin studies in parallel.